Stock ANGEN ANATOLIA TANI VE BIYOTEKNOLOJI ÜRÜNLERI AR-GE SANAYI TICARET
Add to a list
To use this feature you must be a member
Log inSign up

Financials Anatolia Tani ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret

Equities

ANGEN

TREANGN00028

Biotechnology & Medical Research

Market Closed - Borsa Istanbul
Other stock markets
 11:09:30 2024-05-15 EDT 		5-day change 1st Jan Change
13.18 TRY +0.53% Intraday chart for Anatolia Tani ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret -7.12% +5.86%
05-10 Anatolia Tani ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.S. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Anatolia Tani ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.S. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Valuation

Fiscal Period: December 2021 2022
Capitalization 1 3,212 4,741
Enterprise Value (EV) 1 2,701 4,330
P/E ratio 5.1 x 14.3 x
Yield - 2.76%
Capitalization / Revenue 7.83 x 17.6 x
EV / Revenue 6.59 x 16.1 x
EV / EBITDA 8.48 x 27.5 x
EV / FCF 35,680,324 x -439,718,036 x
FCF Yield 0% -0%
Price to Book 4.19 x 5.81 x
Nbr of stocks (in thousands) 220,000 220,000
Reference price 2 14.60 21.55
Announcement Date 22-03-03 23-03-10
1TRY in Million2TRY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022
Net sales 1 421.6 410.1 268.8
EBITDA 1 347.3 318.7 157.3
EBIT 1 342.3 308.9 136.4
Operating Margin 81.2% 75.33% 50.73%
Earnings before Tax (EBT) 1 359.7 462.3 340.3
Net income 1 293.4 433.3 330.4
Net margin 69.6% 105.66% 122.9%
EPS 2 1.938 2.862 1.502
Free Cash Flow - 75.71 -9.847
FCF margin - 18.46% -3.66%
FCF Conversion (EBITDA) - 23.76% -
FCF Conversion (Net income) - 17.47% -
Dividend per Share - - 0.5958
Announcement Date 22-03-03 22-03-03 23-03-10
1TRY in Million2TRY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022
Net Debt 1 - - -
Net Cash position 1 105 511 411
Leverage (Debt/EBITDA) - - -
Free Cash Flow - 75.7 -9.85
ROE (net income / shareholders' equity) - 76.3% 40.9%
ROA (Net income/ Total Assets) - 30.8% 9.93%
Assets 1 - 1,409 3,327
Book Value Per Share 2 2.050 3.490 3.710
Cash Flow per Share 2 0.8900 2.100 1.470
Capex 1 69.6 77.4 94.1
Capex / Sales 16.51% 18.88% 35.01%
Announcement Date 22-03-03 22-03-03 23-03-10
1TRY in Million2TRY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
13.11 TRY
Average target price
15.4 TRY
Spread / Average Target
+17.47%
Consensus

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ANATOLIA TANI VE BIYOTEKNOLOJI ÜRÜNLERI AR-GE SANAYI TICARET Stock Anatolia Tani ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret
+5.86% 89.39M
MODERNA, INC. Stock Moderna, Inc.
+29.77% 49.18B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.00% 42.11B
LONZA GROUP AG Stock Lonza Group AG
+50.47% 40.37B
CELLTRION, INC. Stock Celltrion, Inc.
-5.26% 28.85B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.68% 26.09B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.99% 18.71B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+8.22% 13.26B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+32.41% 12.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.62% 11.99B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ANGEN Stock
  4. Financials Anatolia Tani ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW